Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Julphar
Farmers Insurance
Deloitte
UBS
US Department of Justice
Accenture
Argus Health
Harvard Business School
McKesson

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,883,842 protect, and when does it expire?


Patent ► Subscribe protects FARYDAK and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.

Summary for Patent: ► Subscribe

Title:Use of HDAC inhibitors for the treatment of myeloma
Abstract: The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I) ##STR00001## wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular, multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising an HDAC inhibitor and a compound effecting apoptosis of myeloma cells, preferably bortezomib, for simultaneous, separate or sequential use; to methods of treating myeloma; and to a pharmaceutical composition comprising said combination.
Inventor(s): Atadja; Peter W (Acton, MA)
Assignee: Novartis AG (Basel, CH)
Application Number:12/717,373
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-001Feb 23, 2015RXYesNo► Subscribe► Subscribe TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-002Feb 23, 2015RXYesNo► Subscribe► Subscribe TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-003Feb 23, 2015RXYesYes► Subscribe► Subscribe TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2008107871► Subscribe
Portugal1912640► Subscribe
Mexico2008001610► Subscribe
South Korea101354237► Subscribe
South Korea20080031937► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Accenture
Queensland Health
Julphar
Citi
US Army
UBS
Covington
Farmers Insurance
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot